RxSight, Inc. to Present at the Piper Sandler Healthcare Conference
RxSight, Inc. announced that its management is scheduled to present at the Piper Sandler 38th Annual Healthcare Conference on Tuesday, December 1, 2026, at 4:00 p.m. ET in New York City. A live webcast and archived replay of the presentation will be available on the company’s investor relations website. RxSight is an ophthalmic medical device company known for its Light Adjustable Lens™ system, which allows for post-surgery vision customization after cataract surgery.
RxSight, Inc. to Present at the Piper Sandler Healthcare Conference
RxSight, Inc. (NASDAQ: RXST) announced that its management will present at the Piper Sandler 38th Annual Healthcare Conference on December 1, 2026, in New York City. A live webcast and archived replay of the presentation will be available on the company's investor relations website. RxSight is an ophthalmic medical device company known for its Light Adjustable Lens™ system, which allows for post-surgery vision customization for cataract patients.
Steven A. Cohen reports beneficial ownership of 1.43M RxSight (RXST) shares.
Point72 Asset Management, L.P., its general partner Point72 Capital Advisors, Inc., and Steven A. Cohen have collectively reported beneficial ownership of 1,432,626 shares of RxSight, Inc. (RXST) common stock, representing a 3.4% passive stake as of September 30, 2026. The filing, an amended Schedule 13G/A, indicates shared voting and dispositive power over these shares, with no direct ownership by the reporting persons. This disclosure highlights a significant institutional investment in RxSight.
Form 4 Rxsight Inc: Eric Weinberg (Officer) For: 15 September By Investing.com
This article reports on a Form 4 filing for Rxsight Inc, indicating an insider transaction by Eric Weinberg, an officer of the company. The transaction was recorded for September 15. The article highlights the company's stock symbol, RXST, and mentions its current performance.
Form 4 Rxsight Inc: Eric Weinberg (Officer) For: 15 September By Investing.com
This article from Investing.com announces a Form 4 filing for Rxsight Inc, detailing an insider transaction by Eric Weinberg, an officer of the company, on September 15. The brief report highlights the transaction under the stock symbol RXST.
What RxSight (RXST) Said on Its Q3 Earnings Call
RxSight (RXST) reported a 19% decrease in Q3 revenue to $24.6 million, attributing the decline to competitive pressure, seasonal effects, and disruption from a commercial restructuring and sales-force expansion. The company posted a net loss of $16.2 million. CEO Aziz Mottiwala outlined a strategy to strengthen the U.S. LAL business, advance next-generation adjustable-lens pipeline, and execute its collaboration with Alcon, while shifting focus from new Light Delivery Device (LDD) placements to increasing LAL procedure volume within the existing install base.
RxSight, Inc. (RXST) Reports Q3 Loss, Lags Revenue Estimates
RxSight, Inc. (RXST) reported a narrower-than-expected Q3 loss of $0.21 per share, beating the Zacks Consensus Estimate of $0.29, but its revenues of $24.59 million missed estimates by 10.56%. The company's shares have declined significantly year-to-date, and its stock currently holds a Zacks Rank #3 (Hold).
RXST: Q3 sales and procedures declined; rebuilding LAL utilization and lowering 2027 OpEx are priorities
RxSight, Inc. (RXST) reported a 19% year-over-year decline in Q3 revenue due to decreased Light Adjustable Lens (LAL) procedures, influenced by competitive pressures, seasonality, and commercial restructuring. The company's immediate priorities include increasing LAL utilization in the U.S., advancing its lens product pipeline, and strengthening its collaboration with Alcon, with a focus on reducing operating expenses by 2027. This information is based on the Q3 2026 audio transcript from November 3, 2026.
RxSight Plans to Resume 2027 Guidance After Withholding 2026 Outlook
RxSight announced its intention to resume issuing financial guidance for 2027, following its decision to withhold a formal outlook for 2026. The company anticipates reduced operating expenses in 2027 due to restructuring savings. Management attributed the earlier withholding of 2026 guidance to seasonality, competitive pressures from free-product trials, and internal disruptions related to restructuring and territory adjustments.
Stifel cuts RxSight stock price target on competitive pressures
Stifel has lowered its price target for RxSight Inc. (NASDAQ:RXST) from $7.00 to $5.00, maintaining a Hold rating, due to soft third-quarter results and increasing competitive pressures from products like PureSee. Despite the stock trading down 56% year-to-date, InvestingPro analysis suggests it is undervalued, and the company has a strong current ratio and cash position. However, competitive headwinds are expected to worsen before improving, necessitating a potentially lengthy turnaround.
RxSight Inc (RXST) (Q3 2026) Earnings Call Highlights: Revenue Slides 19% as Sales Force ...
RxSight Inc reported a 19% year-over-year revenue decline to $24.6 million in Q3 2026, with LAL procedure volume down 11% due to competitive pressures and internal disruption from a sales force expansion and restructuring. Despite these challenges, the company strengthened its commercial leadership, nearly doubled its US sales force, and advanced its next-generation adjustable lens pipeline while solidifying a $60 million upfront payment from its Alcon collaboration. RxSight expects Q4 LAL sales to be more in line with Q2 and aims to resume 2027 guidance with its Q4 results, anticipating meaningful cost savings from the restructuring.
RxSight Q3 2026 Earnings Call Transcript
RxSight reported a 19% year-over-year revenue decline in Q3 2026, reaching $24.6 million, largely due to competitive pressures on Light Adjustable Lens (LAL) procedure volumes. To counteract this, the company has nearly doubled its salesforce, aiming to deepen LAL adoption, strengthen its U.S. commercial business, and advance its next-generation adjustable lens pipeline. Despite current challenges, RxSight is confident in its strategic focus, including a positive collaboration with Alcon and a restructuring initiative expected to yield cost savings from 2027 onward, with formal guidance resuming next year.
RxSight, Inc. (RXST) Tops Q3 EPS by 8c
RxSight, Inc. (RXST) announced its Q3 earnings, reporting an EPS of ($0.21), which surpassed analyst estimates by $0.08. However, the company's revenue for the quarter was $24.6 million, falling short of the consensus estimate of $27.19 million.
RxSight, Inc. Reports Third Quarter 2026 Results
RxSight, Inc. announced its third quarter 2026 financial results, reporting total revenue of $24.6 million, down 19% from the prior year, primarily due to competitive pressures. The company highlighted strategic advancements including strengthening commercial leadership, nearly doubling its sales force, and completing an organizational restructuring. Despite a net loss of $(16.2) million, RxSight ended the quarter with $254.7 million in cash, cash equivalents, and short-term investments, including $60 million from the Alcon collaboration.
A listed 5.1% stake sits alongside a 5%-or-less ownership statement at RxSight (RXST).
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander filed an amended Schedule 13G/A for RxSight, Inc. (RXST), stating they have ceased to beneficially own more than 5% of the company's common stock. Despite this, each reporting person's cover page still lists a 5.1% ownership, equating to 2,142,052 shares with shared voting and dispositive power. The filing was made on November 2, 2026, and accepted by the SEC on the same day.
Rxsight (RXST) Stock Price, Chart & Analysis
This article provides a detailed analysis of Rxsight (RXST) stock, including its latest price, key financial figures, and quality scores. It covers valuation, growth, margins, debt, and dividend information, noting the company pays no dividend and has more cash than debt. The analysis also includes a "Belegger score" based on Buffett and Lynch metrics, and various future scenarios based on analyst forecasts.
RxSight, Inc. (RXST) Seasonal Returns Chart
This article presents the seasonal returns chart for RxSight, Inc. (RXST), detailing the average monthly price return from 2021 to 2026. It also provides current stock information, including the real-time Nasdaq price and after-hours trading data. The company's Q3 2026 earnings call is scheduled for November 3, 2026.
BlackRock can vote 2.78M RxSight (RXST) shares as it updates its passive stake.
BlackRock, Inc. has filed an amended passive investment disclosure (SCHEDULE 13G/A) for RxSight, Inc. (RXST), reporting beneficial ownership of 2,851,023 common shares, which represents a 6.9% stake in the company. The filing indicates that BlackRock holds sole voting power over 2,782,168 shares and sole dispositive power over all 2,851,023 shares. This update reflects BlackRock's continued significant passive investment in RxSight.
Weekly Recap: Hires for Light Adjustable Lens and Commercial metrics
RxSight, Inc. (NASDAQ:RXST) is enhancing its commercialization efforts for the Light Adjustable Lens by appointing Taryn Conway as Chief Commercial Officer and Frank Shields as EVP of Sales and Commercial Strategy. The company is linking these hires to key commercial metrics such as account additions, utilization rates, and revenue targets, and has granted inducement options and RSUs to align sales execution with long-term goals. These strategic moves aim to boost the product's market presence and achieve sustained growth.
RxSight, Inc. Estimates – NASDAQ:RXST
This article provides an overview of RxSight, Inc. (NASDAQ: RXST) financial data and analyst estimates available on TradingView. It highlights sections for income statement, balance sheet, cash flow, and valuation metrics, allowing users to compare actual results with estimates and visualize trends. The content emphasizes that it is not investment advice and encourages users to conduct their own research.
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
RxSight, Inc. announced the granting of inducement stock options to purchase 236,456 shares and agreed to grant restricted stock units (RSUs) covering 637,449 shares to two new non-executive officer employees. These grants, made on October 23, 2026, and anticipated on or about November 3, 2026 for RSUs, are an inducement for their employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The awards are subject to specific vesting schedules over several years.
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
RxSight, Inc. announced inducement grants of stock options and restricted stock units to 21 new employees. These grants were approved by the Compensation Committee of the company's Board of Directors and were made outside of RxSight's 2023 Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are intended to incentivize the new hires to contribute to the company's long-term growth.
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
RxSight, Inc. announced the grant of inducement stock options and restricted stock units (RSUs) to two new non-executive officer employees. These grants, totaling 236,456 shares for options and 637,449 shares for RSUs, were made in connection with their new employment and are permitted under Nasdaq Listing Rule 5635(c)(4). The awards have specific vesting schedules tied to continued service.
RxSight Inc. Q3FY26 Results: Earnings call set for November 3, 2026
RxSight Inc. will release its Q3 2026 financial results after market close on November 3, 2026, with an earnings conference call scheduled for 4:30 pm Eastern Time. The company, which specializes in adjustable intraocular lens technology for cataract surgery, will discuss its quarterly performance. Investors can access the live broadcast and archived recording via the company's investor relations website.
RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3
RxSight, Inc. (NASDAQ: RXST) announced it will report its third-quarter 2026 financial results on Tuesday, November 3, 2026, after market close. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results, with call-in details provided for participants and a live broadcast available on its investor relations website. An archived recording will also be accessible via the same link.
RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3
RxSight, Inc. (NASDAQ: RXST) announced it will report its third-quarter 2026 financial results after market close on Tuesday, November 3, 2026. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss these results. Interested parties can access the call via phone or a live webcast on the company's investor relations website.
RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3
RxSight, Inc. announced that it will release its financial results for the third quarter of 2026 on Tuesday, November 3, 2026, after the market closes. The company will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss these results. An archived recording of the call will be available on the company's investor relations website.
RxSight Appoints Two Eyecare Industry Leaders to Drive Commercial Transformation
RxSight, Inc. has announced the appointment of Taryn Conway as chief commercial officer and Frank Shields as executive vice president of sales and commercial strategy. These strategic hires are part of the company's commercial transformation aimed at strengthening its leadership and accelerating the adoption of its light adjustable lens (LAL) technology. Both leaders bring extensive eyecare industry experience, with track records in building commercial organizations and driving the adoption of innovative technologies.
RxSight Appoints Taryn Conway as Chief Commercial Officer, Frank Shields as EVP of Sales and Commercial Strategy
RxSight, Inc. (NASDAQ: RXST) has appointed Taryn Conway as Chief Commercial Officer and Frank Shields as Executive Vice President of Sales and Commercial Strategy. These appointments aim to strengthen the company's commercial leadership and expand the adoption of its Light Adjustable Lens (LAL) technology. The move is part of a broader strategy to enhance sales execution, improve relationships with eye care professionals, and increase the utilization of RxSight's technology in cataract surgery practices.
RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation
RxSight, Inc. (NASDAQ: RXST) announced the appointments of Taryn Conway as Chief Commercial Officer and Frank Shields as Executive Vice President of Sales and Commercial Strategy. These appointments aim to strengthen the company's commercial leadership, enhance execution, and accelerate the adoption of RxSight’s Light Adjustable Lens™ (LAL™) technology. The move is part of a broader commercial transformation to deepen customer engagement and support, helping practices integrate this differentiated technology.
A sales leader with over 30 years in eye care joins RxSight.
RxSight (NASDAQ: RXST) has appointed Taryn Conway as Chief Commercial Officer and Frank Shields as Executive Vice President of Sales and Commercial Strategy. These appointments are part of a broader commercial transformation aimed at enhancing customer engagement and accelerating the adoption of RxSight's Light Adjustable Lens technology. Conway brings over 20 years of experience in eye care, pharmaceuticals, and medical aesthetics, while Shields adds more than 30 years of ophthalmology leadership experience.
Latham & Watkins Advises RxSight on Collaboration With Alcon to Develop Adjustable PCIOLs
Latham & Watkins LLP advised RxSight, Inc. on its non-exclusive collaboration with Alcon to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). The collaboration will combine RxSight’s post-operative light-adjustable technology with Alcon’s PCIOL optical designs to enable surgeons to fine-tune visual outcomes for cataract patients. The Latham & Watkins team was led by New York partner Aaron Gardner and San Diego counsel Robert Yeh, with associate Patrick Chew.
K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world
K2 Vision has been recognized by RxSight, the manufacturer of the Light Adjustable Lens (LAL), as the highest-volume LAL practice globally, having performed over 5,000 LAL procedures. This lens allows post-surgery adjustments to fine-tune a patient's vision, offering a customized solution. K2 Vision's founding surgeon, Dr. Andrew Kopstein, is noted for his extensive experience in lens-based procedures, and the practice serves patients across the Pacific Northwest and Arizona.
K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world
K2 Vision has been recognized by RxSight, the manufacturer of the Light Adjustable Lens (LAL), as the highest-volume LAL practice globally, having performed over 5,000 LAL procedures. The LAL is unique because it allows for post-surgery vision adjustments through noninvasive light treatments, providing a customized vision solution for patients. Dr. Andrew Kopstein, a founding surgeon at K2 Vision, highlighted the benefits of this technology, which allows fine-tuning based on a patient's actual vision needs.
RxSight announces Alcon lens deal as analysts target RxSight stock at USD 8.17
RxSight has announced a non-exclusive collaboration with Alcon for up to $200 million to develop adjustable presbyopia-correcting intraocular lenses. This deal allows RxSight to expand beyond cataract surgery, though its second-quarter product sales fell and gross margins declined. Despite this, twelve firms have assigned RxSight a consensus target of USD 8.17, with the company's next earnings report expected on November 4, 2026.
RxSight announces Alcon lens deal as analysts target RxSight stock at USD 8.17
RxSight has announced a non-exclusive collaboration with Alcon for up to $200 million to develop adjustable presbyopia-correcting intraocular lenses. This deal allows RxSight to expand its lens technology beyond cataract surgery while leveraging Alcon's optical designs. Despite this collaboration, product sales for RxSight declined, and analysts have a cautious outlook, assigning a consensus target of $8.17.
Watkins Advises RxSight on Collaboration With Alcon to Develop Adjustable PCIOLs
Latham & Watkins LLP advised RxSight in a non-exclusive collaboration with Alcon to co-develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). This partnership aims to combine RxSight's light-adjustable technology with Alcon's PCIOL optical designs to allow surgeons to fine-tune visual outcomes for cataract patients. The Latham & Watkins life sciences licensing team was led by Aaron Gardner and Robert Yeh.
Jefferies cuts target for RxSight stock to USD 5.75
Jefferies has reduced its target for RxSight (RXST) stock to USD 5.75 from USD 6.50, maintaining a Hold rating. This adjustment follows RxSight's Q2 2026 revenue of USD 33.74 million, which exceeded consensus, alongside continued losses. The investment case now heavily centers on the execution of RxSight's commercial reset and the potential impact of its collaboration with Alcon.
Is the New Setup at RxSight (NASDAQ:RXST) Sustainable?
RxSight (NASDAQ:RXST) is currently under scrutiny due to tight financial conditions emphasizing the importance of funding runway and company-specific demand. The article questions whether the company's focus on adjustable intraocular lenses can lead to sustainable and repeatable execution. Investors are advised to look for strong internal disclosures from management regarding demand, delivery, and capital allocation rather than relying solely on market sentiment.
RxSight stock faces a lower Jefferies target at USD 5.75
RxSight, Inc. (RXST) reported a Q2 2026 adjusted loss of USD 0.29 per share, outperforming the consensus of USD 0.33, with revenues of USD 33.74 million. Despite the revenue beat and better-than-expected loss, the company remains unprofitable. Jefferies and Bank of America have both lowered their price targets for RxSight stock to USD 5.75 and USD 5.50 respectively, maintaining "Hold" and "Underperform" ratings, reflecting caution despite the quarterly performance.
Analysts Offer Insights on Healthcare Companies: RxSight (RXST) and Armata Pharmaceuticals (ARMP)
This article summarizes recent analyst ratings for two healthcare companies: RxSight (RXST) and Armata Pharmaceuticals (ARMP). Bank of America Securities reiterated a Sell rating on RxSight with a $5.50 price target, while H.C. Wainwright maintained a Buy rating on Armata Pharmaceuticals with a $15.00 price target. The article also provides details on the analysts' rankings and the overall consensus ratings for both stocks.
RxSight stock falls 1.62 percent as target cuts mount
RxSight stock dropped 1.62 percent to USD 4.85 following analyst target cuts from Bank of America and Jefferies, despite Q2 2026 revenue exceeding consensus estimates. The company's management presented a turnaround plan focusing on Light Adjustable Lens growth amidst flat commercial performance and withdrawn 2026 guidance, making execution a critical factor for investor confidence. The stock is currently trading near its 52-week low.
RxSight Price Target Cut to $5.75/Share From $6.50 by Jefferies
Jefferies has lowered its price target for RxSight (NASDAQ: RXST) shares to $5.75 from $6.50. The firm maintained a "Buy" rating on the stock despite the revised price target.
RxSight's Utilization-Growth Upside Faces Structural, Competitive Headwinds, BofA Says
Bank of America (BofA) indicates that RxSight (RXST) possesses upside potential contingent on its ability to expand its salesforce and implement utilization-growth initiatives. However, the company faces significant structural and competitive challenges that could impede this growth. Full details of BofA's analysis are available to premium subscribers.
RXSIGHT, INC. : JEFFERIES CUTS TARGET PRICE TO $5.75 FROM $6.50
Jefferies has reduced its target price for RXSIGHT, INC. (RXST.O) to $5.75 from $6.50. This information was reported by Reuters on September 22, 2026. The article's content reflects only the author's opinion and is not intended as investment advice.
BofA Adjusts Price Target on RxSight to $5.50 From $6.50
BofA has adjusted its price target for RxSight (RXST) to $5.50 from $6.50. Despite this change, the company currently holds an average analyst rating of "hold" with a mean price target of $7.57. The full MT Newswires article requires a premium subscription to view.
RxSight, Inc. (RXST) insider now holds 235,516 shares after option exercise
RxSight, Inc.'s Chief Business Development Officer, Eric Weinberg, exercised 35,168 stock options on September 15, 2026, increasing his direct holdings to 235,516 shares. He also holds significant indirect ownership through a trust and his spouse. The exercised options were fully vested.
RxSight (RXST) ends employee option swap after 91.9% take-up
RxSight (RXST) has completed its employee option exchange offer, with 91.9% of eligible options tendered and cancelled. This involved 205 employees exchanging 3.76 million option shares for new equity awards. The company subsequently granted new options to executives and restricted stock units to non-executive employees under its 2021 Equity Incentive Plan.
RxSight management is scheduled to speak in Boston on Sept. 9
RxSight (NASDAQ: RXST) announced that its management will participate in the Wells Fargo Healthcare Conference in Boston, Massachusetts, on Wednesday, September 9, 2026, at 9:30 a.m. ET. A live and archived webcast of the presentation will be available on the company’s investor relations website. The announcement highlights the company's engagement with the investment community and provides details for interested parties to access the presentation.
RxSight at wells fargo healthcare conference: reset centers on LAL growth
RxSight presented at the Wells Fargo 21st Annual Healthcare Conference, outlining a turnaround plan focused on increasing Light Adjustable Lens (LAL) utilization among existing surgeons rather than acquiring new accounts. The company plans to double its U.S. sales force through resource reallocation and emphasizes the strategic importance of its partnership with Alcon, which provides $200 million upfront and a 30% royalty on future sales. RxSight believes its LAL technology offers superior clinical outcomes and aims to position "adjustable cataract surgery" as a distinct category to drive future growth.